Merck KGaA (FRA:MRK) Given Average Rating of “Hold” by Brokerages

Merck KGaA (FRA:MRK) has been given an average rating of “Hold” by the twenty ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is €100.53 ($116.89).

Several research firms recently issued reports on MRK. DZ Bank reiterated a “neutral” rating on shares of Merck KGaA in a report on Tuesday, April 2nd. Sanford C. Bernstein set a €108.00 ($125.58) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, April 15th. Barclays set a €82.00 ($95.35) price objective on Merck KGaA and gave the stock a “sell” rating in a report on Friday, May 3rd. JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, May 13th. Finally, UBS Group set a €104.00 ($120.93) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, May 13th.

MRK stock opened at €91.96 ($106.93) on Friday. Merck KGaA has a 12-month low of €76.60 ($89.07) and a 12-month high of €115.00 ($133.72). The business has a 50-day moving average price of €91.15.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: How are the companies in the S&P 500 selected?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.